ClinicalTrials.gg
Not yet recruitingNCT07389525Updated Nov 18, 2026

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

An Early Phase 1 interventional study of ICI Therapy in Gastrointestinal Neoplasms, Genitourinary Cancer and Thoracic Cancer, sponsored by Indiana University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Indiana University · Early Phase 1, Interventional, and Basic science

How we know

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
107th of 245
80 · median 60
Started
2027
the only one that year
Phase 1
56 of 316
12 open now
Primary completion
2027-12
later than 65 of 113 live
Registered
305th of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 107th largest by planned enrollment of the 245 interventional ones that give a count, is the only one that started in 2027, is one of 56 in phase 1, reaches primary completion later than 65 of the 113 other live ones, and was the 305th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.

Read the detailed description

Findings suggest that adverse events during checkpoint inhibitor therapy may, in part, be caused by drug-drug interactions that increase the risk of adverse events with co-administered medications. Identifying these novel drug-drug interactions will likely inform clinical strategies to reduce adverse events during checkpoint inhibitor therapy and enhance their clinical benefits.

This current research aims to systematically explore the impact of ICIs on CYP/transporter function and the associated risks for adverse events, thereby informing clinical strategies to mitigate these risks and optimize the therapeutic benefits of checkpoint inhibitors. By employing a rigorous crossover drug-drug interaction design, this study seeks to enhance understanding of drug interactions during ICI therapy, ultimately improving patient outcomes in oncology.

The long-term goal of this research is to find ways to manage adverse events that occur during treatment with ICIs. The research has two main aims:

  1. To understand how ICI therapy affects the metabolism of certain drugs named CYP/transporter probe drugs and to also understand the risk of side effects from commonly prescribed drugs that are affected by these enzymes and transporters in cancer patients.
  2. To examine the relationship between levels of pro-inflammatory cytokines (signaling molecules involved in inflammation) and how well these probe drugs are metabolized before and during ICI therapy.

A two-phase clinical study will be conducted to achieve these aims: patients will be given seven different probe drugs that interact with key enzymes and transporters (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A, BCRP, and SLCO1B1) both before they start ICI treatment and after they have begun therapy.

Adverse events will be assessed by looking at how changes in the function of these enzymes and transporters affect the metabolism of drugs that cancer patients commonly use. Special computer models, known as physiologically-based pharmacokinetic (PBPK) models, will be used to simulate how these drugs behave in the body and predict potential serious adverse events.

03

Conditions studied

  • Gastrointestinal Neoplasms
  • Genitourinary Cancer
  • Thoracic Cancer
  • Sarcoma
  • Melanoma

Keywords

  • cytokines
  • immune checkpoint inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years old at the time of
  • Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)
  • Ability to provide written informed consent and HIPAA authorization

Exclusion criteria

Exclusion Criteria:

  • Actively pregnant or breastfeeding
  • Body weight less than 50 kg or a >35
  • Low baseline , defined as \<10 g/dL

    • Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)
  • Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or >96 U/L, alanine aminotransferase > 80 IU/L, alkaline phosphatase >260 U/L, or total > 2.6 mg/dL

    • Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)
  • Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated \<45 mL/minute/1.73 m2 BSA

    • Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)
  • Poor performance status that makes it unlikely the patient will complete 3 cycles of (at the treating oncologist's discretion)
  • Diagnosis or past medical history of disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis
  • History of intolerance, allergic reaction, or to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)
  • Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)
  • Concomitant treatment with systemic drugs (see Appendix 3 for list)

    • Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
  • Concomitant treatment with a CYP/transporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list)

    • Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
  • Are unwilling/unable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study
  • Inability to take oral medication
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    CYP enzyme/drug transporter probe substrates administered at two study visits: one before initiation of ICI therapy and one while on therapy.

    Drug: ICI Therapy

  • Experimental
    Cohort 2

    CYP enzyme/drug transporter probe substrates administered at one study visit: during ICI therapy.

    Drug: ICI Therapy

Interventions

  • DrugICI Therapy

    Low dose of a cocktail of probe substrates for eight major CYP enzymes/drug transporters.

06

What researchers measure

Primary outcomes

  1. Change in plasma concentrations from drug exposure during ICI therapy

    Time frame: baseline (before start of ICI therapy) up to day 84

  2. Toxicity concentrations for CYP/transporter substrate drugs in plasma

    Time frame: baseline (day before Cycle 1 start) up to day 84

  3. Associations between pro-inflammatory cytokine concentrations and CYP/transporter probe drug concentrations in plasma

    Time frame: baseline (day before Cycle 1 start) up to day 84

Secondary outcomes

  1. Assess associations between T cells populations and CYP/transporter probe drug concentrations

    Peripheral blood mononuclear cells (PBMCs)

    Time frame: baseline (day before Cycle 1 start) up to day 84

  2. Concentrations of endogenous biomarkers

    Plasma or urine

    Time frame: baseline (day before Cycle 1 start) up to day 84

  3. CYP/transporter endogenous biomarker concentrations

    Plasma or urine correlated with plasma concentrations of pro-inflammatory cytokines

    Time frame: baseline (day before Cycle 1 start) up to day 84

  4. Correlation of concentration of population of activated T cells and CYP/transporter endogenous biomarkers

    Plasma or urine

    Time frame: baseline (day before Cycle 1 start) up to day 84

  5. CYP/transporter substrate-related adverse events and immune related (ir) adverse events

    assessed through surveys given to participants

    Time frame: Baseline (before starting ICI cycle 1) and study visit 2 (up to day 84)

07

Study locations

1 site
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
    • Ross Robinson · Contactrossrobi@iu.edu · 317-381-1426
    • Tyler Shugg, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 50 phase 1 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 71. This study's planned 11 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Sep 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07389525
Lead sponsor
Indiana University
Responsible party
Tyler Andrew Shugg (Assistant Professor, Indiana University) — Principal investigator
First posted
Feb 5, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Ross Robinson
Contact
rossrobi@iu.edu
317-381-1426
Tyler Shugg, MD
principal investigator · IUSCCC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion